Shivam Rai

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F.

Journal: Leukemia
Published: June 10, 2024

IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.

IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.

Journal: Blood advances
Published: August 01, 2023

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

The glutaminase inhibitor CB-839 targets metabolic dependencies of JAK2-mutant hematopoiesis in MPN.

Journal: Blood advances
Published: June 12, 2023

Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.

Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies.

Journal: Nature biomedical engineering
Published: March 08, 2023

Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.

Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms.

Journal: HemaSphere
Published: December 07, 2022

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.

Iron is a modifier of the phenotypes of JAK2-mutant myeloproliferative neoplasms.

Journal: Blood
Published: August 01, 2022

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm.

Journal: Nature communications
Published: July 08, 2021

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages.

MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages.

Journal: Blood
Published: February 05, 2020

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.

JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms.

Journal: Blood
Published: February 14, 2019

Tracking of epigenetic changes during hematopoietic differentiation of induced pluripotent stem cells.

Tracking of epigenetic changes during hematopoietic differentiation of induced pluripotent stem cells.

Journal: Clinical epigenetics
Published: November 05, 2018
Showing 1-10 of 10

Last Updated: 09/26/2026